News

The virus has not yet evolved to spread efficiently between people. Excellent vaccine technology exists, but the government ...
RNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed ...
Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...
Moderna on Monday said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot in a late-stage trial, clearing a path forward for the product and ...
The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...
Moderna stock veered higher Monday after its flu shot proved to be as effective as older technology in a final-phase study.
The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...
The FDA has updated labels on the top two COVID-19 vaccines to warn of a rare heart side effect, mostly seen in young men.